Clinical Trial Update: The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. [Phase 1]

View source ↗

Summary

Phase 1 open-label PET study to evaluate AZD2389 FAP occupancy in the liver of participants with advanced liver fibrosis. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Liver Fibrosis

Drugs mentioned

• AZD2389

Snippet

Sponsor: AstraZeneca | Conditions: Liver Fibrosis, Hepatic Cirrhosis | Phase 1 | Status: RECRUITING